Datapoint: Gilead Shores Up Breast Cancer Indication for Trodelvy

The FDA last week granted Gilead Sciences’ Trodelvy full approval for the treatment of triple-negative breast cancer (TNBC) — clearing the drug for use in TNBC patients who have received two or more prior treatments, with at least one treatment administered in a metastatic setting. Previously, the drug was approved for use in patients who had received at least two prior treatments in a metastatic setting. Trodelvy, which Gilead picked up via its $21 billion acquisition of Immunomedics, Inc. last October, currently holds preferred formulary placement for just 3% of all covered lives. It is not covered for 23% of all insured lives.

SOURCE: MMIT Analytics, as of 4/9/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 19

Datapoint: Lilly Scores Diabetes, Obesity Nods for Mounjaro

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 18

Datapoint: CDPHP Selects New PBM

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 17

Datapoint: Oscar to Exit Two States

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today